XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2024

 

 

2023

 

Noncurrent deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

51,777

 

 

$

45,472

 

Contribution carryforwards

 

 

26

 

 

 

34

 

Lease liability

 

 

1,671

 

 

 

2,116

 

Deferred revenue

 

 

5,681

 

 

 

20,337

 

Capitalized R&D costs

 

 

31,282

 

 

 

28,732

 

Other assets

 

 

14,845

 

 

 

14,962

 

Tax credits

 

 

33,701

 

 

 

30,757

 

Less: valuation allowance

 

 

(136,872

)

 

 

(139,133

)

Total deferred tax assets, noncurrent

 

 

2,111

 

 

 

3,277

 

 

 

 

 

 

 

Noncurrent deferred tax liability:

 

 

 

 

 

 

Investments and other

 

 

577

 

 

 

 

Deferred gain - Imugene

 

 

 

 

 

1,303

 

Right of use asset

 

 

1,534

 

 

 

1,974

 

Total deferred tax liabilities, noncurrent

 

 

2,111

 

 

 

3,277

 

Net deferred tax assets

 

$

 

 

$

 

Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit

The reasons for the difference between actual income tax benefit for the years ended December 31, 2024 and December 31, 2023 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands):

 

 

 

Year Ended December 31, 2024

 

 

Year Ended December 31, 2023

 

 

 

Amount

 

 

% of Pre-Tax
Loss

 

 

Amount

 

 

% of Pre-Tax
Loss

 

Income tax expense at statutory rate

 

$

1,501

 

 

 

21.0

%

 

$

(12,877

)

 

 

21.0

%

State income taxes, net of federal tax benefit

 

 

46

 

 

 

0.6

%

 

 

(1,774

)

 

 

2.9

%

Non-deductible expenses

 

 

97

 

 

 

1.4

%

 

 

81

 

 

 

0.0

%

Stock compensation - nondeductible

 

 

1,032

 

 

 

14.4

%

 

 

681

 

 

 

(1.2

%)

Stock compensation - forfeitures

 

 

1,136

 

 

 

15.9

%

 

 

3,176

 

 

 

(5.2

%)

Change in fair value

 

 

(6,507

)

 

 

(91.1

%)

 

 

4

 

 

 

0.0

%

Change in state impact on IRC section 174

 

 

(553

)

 

 

(7.7

%)

 

 

 

 

 

 

R&D and orphan drug credits

 

 

(2,944

)

 

 

(41.2

%)

 

 

(6,078

)

 

 

9.9

%

Other

 

 

(11

)

 

 

(0.1

%)

 

 

657

 

 

 

(1.1

%)

Change in state tax rate

 

 

8,464

 

 

 

118.4

%

 

 

(1,632

)

 

 

2.7

%

Change in valuation allowance

 

 

(2,261

)

 

 

(31.6

%)

 

 

17,762

 

 

 

(29.0

%)

Income tax (benefit) expense

 

$

 

 

 

0.0

%

 

$

 

 

 

0.0

%